

# A study of glycemic control and prevalence of neuropathy and foot ulcers at tertiary health care center

Rajaram L Munde<sup>1</sup>, Chetan R Sarda<sup>2\*</sup>

<sup>1</sup>Associate Professor, <sup>2</sup>Assistant Professor, Department of Medicine, MIMSR Medical College, Latur, Maharashtra, INDIA.

Email: [rajarammunde@gmail.com](mailto:rajarammunde@gmail.com)

## Abstract

**Background:** Diabetes Mellitus (DM) is most common non communicable diseases across the world. **Aims and Objectives:** To study glycemic control and prevalence of neuropathy and foot ulcers at tertiary health care center **Methodology:** This was a cross-sectional study carried out in the known patients of diabetes diagnosed by Glucose tolerance test and attending the OPD or IPD of the department of Medicine of a tertiary health care centre during the one year period i.e. January 2018 to January 2019 the data was entered to excel sheet and analyzed windows excel software for windows 10. **Result :** In our study we have seen that The majority of the patients were in the age group of >70 were 30.23%, followed by 60-70 were 25.58%, 50-60 were 20.93%, 40-50 were 16.28%, 30-40 were 6.98%. The majority of the patients were Male i.e. 68% and Female were 32% The prevalence was maximum with HbA1C 9-10 were 8.84%, followed by 8-9 were 4.88%, 7-8 were 3.95%, 6-7 were 1.16%. The prevalence was maximum with HbA1C 9-10 were 2.56%, followed by 8-9 were 2.09%, In 7-8 were 0.70%, 6-7 were 0.23%. **Conclusion:** It can be concluded from our study as the Glycemic control deranged the prevalence of Peripheral neuropathy and Diabetic foot ulcer increased. **Key Word:** HbA1C, neuropathy, Diabetic foot ulcers (DFU)

## \*Address for Correspondence:

Dr. Chetan R Sarda, Assistant Professor, Department of Medicine, MIMSR Medical College, Latur, Maharashtra, INDIA.

Email: [rajarammunde@gmail.com](mailto:rajarammunde@gmail.com)

Received Date: 21/09/2019 Revised Date: 03/10/2019 Accepted Date: 17/11/2019

DOI: <https://doi.org/10.26611/10211228>

| Access this article online  |  |
|---|--|
| Quick Response Code:  | Website:<br><a href="http://www.medpulse.in">www.medpulse.in</a> |
|  | Accessed Date:<br>20 November 2019                               |

## INTRODUCTION

Diabetes Mellitus (DM) is most common non communicable diseases across the world. Two types of complications are encountered usually with DM: microvascular and macrovascular. Diabetic neuropathy is one of the most commonly-occurring micro vascular complications, of which the most common type is distal symmetrical neuropathy or polyneuropathy. Patients who present with diabetic foot ulceration are heterogeneous. Even though most of them have peripheral polyneuropathy, there are several other factors that may

vary among patients, such as the existence of peripheral arterial disease (PAD), infection and co-morbid conditions. PAD is present in approximately one-half of patients with foot ulcers.<sup>1</sup> Diabetes-related conditions in the lower limb that increases the risk for amputation among people having DM include peripheral neuropathy, PAD, and sepsis. Peripheral neuropathy cause loss of sensation, resulting in inability to recognize foot problems and may lead to development of foot deformities that increase pressure points prone to ulceration. Common risk factors for amputation include older age, male gender, a member of certain racial/ethnic groups, having poor glucose control, having diabetes for a long duration and practicing poor preventive health care.<sup>6</sup> It is estimated that up to 15% of all people with diabetes will eventually develop a foot ulcer and up to 10% of all non-traumatic amputations are performed on patients with diabetes.<sup>2</sup> So in our study seen glycemic control and prevalence of neuropathy and foot ulcers at tertiary health care center

**METHODOLOGY**

This was a cross-sectional study carried out in the known patients of diabetes diagnosed by Glucose tolerance test and attending the OPD or IPD of the department of Medicine of a tertiary health care centre during the one year period i.e. January 2018 to January 2019, so during the one year period there were 430 patients of diabetes were included into the study. All details of the patients like age, sex was noted. All the patients undergone HbA1C test and the prevalence of peripheral neuropathy and diabetic foot ulcer if any were also noted the data was entered to excel sheet and analyzed windows excel software for windows 10.

**RESULT**

**Table 1:** Distribution of the patients as per the age

| Age          | No.        | Percentage (%) |
|--------------|------------|----------------|
| 30-40        | 30         | 6.98           |
| 40-50        | 70         | 16.28          |
| 50-60        | 90         | 20.93          |
| 60-70        | 110        | 25.58          |
| >70          | 130        | 30.23          |
| <b>Total</b> | <b>430</b> | <b>100.00</b>  |

The majority of the patients were in the age group of >70 were 30.23%, followed by 60-70 were 25.58%, 50-60 were 20.93%, 40-50 were 16.28%, 30-40 were 6.98%.

**Table 2:** Distribution of the patients as per the sex

| Sex          | No.        | Percentage (%) |
|--------------|------------|----------------|
| Male         | 292        | 68             |
| Female       | 138        | 32             |
| <b>Total</b> | <b>430</b> | <b>100</b>     |

The majority of the patients were Male i.e. 68% and Female were 32%

**Table 3:** Distribution of the patients as per the prevalence of neuropathy and glycemc control (HbA1C)

| HbA1C        | No.       | Percentage (%) |
|--------------|-----------|----------------|
| 6-7          | 5         | 1.16           |
| 7-8          | 17        | 3.95           |
| 8-9          | 21        | 4.88           |
| 9-10         | 38        | 8.84           |
| <b>Total</b> | <b>81</b> | <b>18.84</b>   |

The prevalence was maximum with HbA1C 9-10 were 8.84%, followed by 8-9 were 4.88%, 7-8 were 3.95%, 6-7 were 1.16%.

**Table 4:** Distribution of the patients as per the prevalence of diabetic foot ulcer and glycemc control (HbA1C)

| HbA1C        | No.       | Percentage (%) |
|--------------|-----------|----------------|
| 6-7          | 1         | 0.23           |
| 7-8          | 3         | 0.70           |
| 8-9          | 9         | 2.09           |
| 9-10         | 11        | 2.56           |
| <b>Total</b> | <b>24</b> | <b>5.58</b>    |

The prevalence was maximum with HbA1C 9-10 were 2.56%, followed by 8-9 were 2.09%, In 7-8 were 0.70%, 6-7 were 0.23%.

**DISCUSSION**

There is a dramatic rise in the prevalence of Type 2 Diabetes Mellitus (T2DM) and its associated complications across the globe. The projected worldwide burden of diabetic patients is estimated to escalate from 135 million in 1995 to 300 million in 2025<sup>6</sup>. In addition, there is an exponential increase in the devastating long-term complications of T2DM including peripheral artery disease<sup>7</sup>, stroke<sup>8</sup>, cardiovascular disorders, biliary tract disease<sup>9</sup>, hyperlipidemia<sup>10</sup>, colorectal cancer<sup>11</sup> and sepsis<sup>12</sup>. A study has reported a prevalence of 8.1%-41.5% for T2DM related retinopathy, 21%-22% for albuminuria, 6.7%-46.3% for nephropathy and 21.9%-60% for neuropathy<sup>13</sup>. Diabetes, once considered as a disease of developed countries, is one of the endo-<sup>3</sup> crine disorders that reached epidemic proportions worldwide now. The metabolic deregulation associated with diabetes mellitus (DM) causes secondary path physiologic changes in multiple organ systems that impose a tremendous burden<sup>4</sup> on the individual with diabetes and on the health care system. Overall all 15% of individuals with diabetes mellitus will have foot ulcer during their lifetime and the annual incidence is 2-3%<sup>5</sup> Owing to a high susceptibility to concomitant infection, hyperlipidemia, and peripheral vasculopathy in diabetic patients, long-standing T2DM invariably lead to neuropathy, lower limb ischemia and Diabetic Foot Ulcers (DFUs). The estimated lifetime risk of a diabetic patient to develop a DFU has been reported to range from reach 15% to 25%<sup>14</sup>. In our study we have seen that The majority of the patients were in the age group of >70 were 30.23%, followed by 60-70 were 25.58%, 50-60 were 20.93%, 40-50 were 16.28%, 30-40 were 6.98%. The majority of the patients were Male i.e. 68% and Female were 32% The prevalence was maximum with HbA1C 9-10 were 8.84%, followed by 8-9 were 4.88%, 7-8 were 3.95%, 6-7 were 1.16%. The prevalence was maximum with HbA1C 9-10 were 2.56%, followed by 8-9 were 2.09%, In 7-8 were 0.70%, 6-7 were 0.23%. From this we can concluded that as the Glycemic control is poor with respect to HbA1C the peripheral neuropathy and Diabetic foot ulcers were common. These findings are similar to Hamdi Almaramhy<sup>15</sup> they found that those majority of patients who had poorly controlled T2DM with advanced stage of DFUs.

## CONCLUSION

It can be concluded from our study as the Glycemic control deranged the prevalence of Peripheral neuropathy and Diabetic foot ulcer increased.

## REFERENCES

1. Pampers L, Huijberts M, Apelqvist J, *et al.* High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale Study. *Diabetologia* 2007;50: 18–25.
2. Department of Health. Improving diabetes services: The NSF two years on. Department of Health, London. Available from: URL: [www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidanceArticle/fs/en](http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en). 2005. (Accessed 12th February 2011).
3. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of Diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 27: 1047-1053.
4. International Diabetes Federation (2012) The Global Burden. IDF Diabetes Atlas Fifth Edition.
5. Amos AF, McCarty DJ, Zimmet P, The rising global burden of diabetes and its complications: estimates and projections to the year 2010, *Diabet Med* 1997; 14 (5) S1–S85.
6. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. *Diab Care* 1998; 21: 1414-1431.
7. Guraya SY, London N. The prevalence and management strategies for peripheral artery disease associated with diabetes mellitus in the Arab world. *J Taibah Univ Med Sci* 2016; 11: 310-316.
8. Lekoubou A, Clovis N, Dzudie A, Kengne AP. Diagnosed diabetes mellitus and in-hospital stroke mortality in a major sub-Saharan African urban medical unit. *Prim Care Diab* 2017; 11: 57-62.
9. Khairy GA, Guraya SY, Murshid KR. Cholesterosis. Incidence, correlation with serum cholesterol level and the role of laparoscopic cholecystectomy. *Saudi Med J* 2004; 25: 1226-1228.
10. Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American heart association. *Circulation* 2016; 134: 535-578.
11. Guraya SY. Association of type 2 diabetes mellitus and the risk of colorectal cancer: A meta-analysis and systematic review. *World J Gastroenterol* 2015; 21: 6026.
12. Trevelin SC, Carlos D, Beretta M, da Silva JS, Cunha FQ. Diabetes mellitus and sepsis: a challenging association. *Shock* 2017; 47: 276-287.
13. Bos M, Agyemang C. Prevalence and complications of diabetes mellitus in Northern Africa, a systematic review. *BMC Publ Health* 2013; 13: 387.
14. Antonopoulos AS, Siasos G, Konsola T, Oikonomou E, Tentolouris N, Kollia C. Arterial wall elastic properties and endothelial dysfunction in the diabetic foot syndrome in patients with type 2 diabetes. *Diab Care* 2015; 38: 180-181.
15. Hamdi Almaramhy, Nehal Anam Mahabbat, Khulood Yahya Fallatah. The correlation of fasting blood glucose levels with the severity of diabetic foot ulcers and the outcome of treatment strategies. *Biomedical Research* .2018 ; 29(9): 1961-1967

Source of Support: None Declared  
Conflict of Interest: None Declared